Jose Luis
Alonso Romero
Asociado Ciencias de la Salud
Queen Mary University of London
Londres, Reino UnidoQueen Mary University of London-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2021
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394